经皮消融治疗肝细胞癌：现状。

Percutaneous ablation of hepatocellular carcinoma: current status.

机构信息

Department of Interventional Radiology, University of California Los Angeles Medical Center, 757 Westwood Plaza, Suite 2125C, Los Angeles, CA 90095, USA.

出版信息

J Vasc Interv Radiol. 2010 Aug;21(8 Suppl):S204-13. doi: 10.1016/j.jvir.2009.11.025.

DOI:10.1016/j.jvir.2009.11.025

PMID:20656230

Abstract

Hepatocellular carcinoma (HCC) is an increasingly common disease with dismal long-term survival. Percutaneous ablation has gained popularity as a minimally invasive, potentially curative therapy for HCC in nonoperative candidates. The seminal technique of percutaneous ethanol injection has been largely supplanted by newer modalities, including radiofrequency ablation, microwave ablation, cryoablation, and high-intensity focused ultrasound ablation. A review of these modalities, including technical success, survival rates, and complications, will be presented, as well as considerations for treatment planning and follow-up.

摘要

肝细胞癌（HCC）是一种越来越常见的疾病，长期生存预后不佳。对于不能手术的 HCC 患者，经皮消融治疗作为一种微创、潜在可治愈的治疗方法，已得到广泛应用。经皮乙醇注射的开创性技术已被包括射频消融、微波消融、冷冻消融和高强度聚焦超声消融在内的新技术所取代。本文将对这些技术进行综述，包括技术成功率、生存率和并发症，并对治疗计划和随访进行讨论。